What Contramal retard Treats: Main Uses and Benefits

Contramal retard is generally applied for the symptomatic management of distressing pain that is persistent and long-lasting, and plays a role in managing continuous analgesia. This prolonged-release medication is relevant in clinical settings where the intensity of pain is difficult to tolerate or is not adequately managed by treatment with nonopioid analgesics. It is commonly used to help with pain reduction associated with conditions such as chronic low back pain and painful osteoarthritis.

Its application is relevant when symptoms are severe enough to require consistent, sustained analgesic support. The sustained pain control generally provides support for assisting with functional comfort. By easing the overall impact of constant pain, this formulation may help reduce interference with a patient's daily activities and routine, often contributing to easing pain-related sleep disruption.

“The primary goal is to support general comfort during periods of sustained symptoms.”

---

Quick Fact: Supportive Management of Persistent Pain

Feature	Description
Symptom Area	Moderate-to-severe pain, chronic in nature
Symptom Focus	Persistent discomfort, pain not adequately managed by nonopioids
Therapeutic Support	Assisting with functional comfort and continuous analgesia
Use Context	Contexts involving a need for sustained symptom support

Eligibility Scope

Populations for whom use is allowed:

• Adults and adolescents above the age of 14 years who require relief for moderate to severe pain.

Populations for whom use is contraindicated (Must Not Use):

• Children younger than 12 years of age.
• Children younger than 18 years following tonsillectomy and/or adenoidectomy.
• Patients with significant respiratory depression or uncontrolled epilepsy.
• Individuals in a state of acute intoxication by alcohol, opioids, hypnotics, or psychotropic medications.
• Patients receiving Monoamine Oxidase (MAO) inhibitors or within 14 days of discontinuing them.
• Use is also contraindicated for the purpose of narcotic withdrawal treatment.

Condition-specific and Age-related Eligibility Rules:

• The prolonged-release formulation is not recommended for patients with severe hepatic insufficiency or severe renal insufficiency due to the risk of delayed elimination.
• Use should be avoided in adolescents (12–18 years) with established risk factors for respiratory depression.
• Elderly patients over 75 years require special consideration, and the dosage interval may need to be extended.

Pregnancy and Lactation Eligibility Status:

• The medicine is not recommended during pregnancy or lactation due to documented risks, including Neonatal Opioid Withdrawal Syndrome.

The official interaction profile of Contramal retard is strictly defined by regulatory documents, focusing on pharmacodynamic reinforcement and metabolic clearance.

Absolute Restrictions and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited and classified as an absolute contraindication. A mandatory period of 14 days must elapse after stopping MAOI therapy before Contramal retard can be initiated. This timing rule is based on the risk of life-threatening interactions.

Drug and Substance Reinforcement

The medicine’s dual action creates pharmacodynamic interactions with other substances. Co-administration with Serotonergic Agents (including SSRIs and Triptans) is documented as increasing the risk of Serotonin Syndrome. Combining the drug with other CNS Depressants, including alcohol, results in an additive CNS depressant effect, formally increasing the risk of profound sedation and respiratory depression. Use with drugs that lower the seizure threshold also increases the overall documented risk of convulsions.

Pharmacokinetic and Exposure Alterations

The drug is metabolized by CYP2D6 and CYP3A4 enzymes. Co-use with strong CYP3A4 Inducers such as Carbamazepine significantly reduces the analgesic effect due to increased metabolic clearance. Conversely, CYP2D6 Inhibitors (e.g., Quinidine) alter the drug's exposure by increasing the plasma level of the parent compound while reducing the concentration of the active M1 metabolite.

Population Notes

The severity of pharmacokinetic interactions is population-dependent. Official documents note that CYP2D6 Ultra-Rapid Metabolizers face an increased risk of adverse events due to higher M1 metabolite exposure, while Poor Metabolizers may have an inadequate analgesic effect. Severe hepatic or renal impairment requires avoidance of the prolonged-release formulation.

The mechanism of action of Contramal retard (Tramadol) is defined by its dual biological function that modulates nociceptive signaling in the Central Nervous System (CNS) through two complementary pathways.

First, the drug acts as a weak agonist at the mu-opioid receptors (MOR). Its active metabolite, O-desmethyl-tramadol (M1), has a significantly higher binding affinity for the MOR. This agonism reduces the excitability of neurons involved in transmitting ascending signals, modulating central nociceptive signal processing. The magnitude of this effect is largely dependent on the metabolic conversion of the parent drug by the CYP2D6 enzyme.

Second, the parent drug inhibits the reuptake of the neurotransmitters Serotonin (5-HT) and Norepinephrine (NE) via the SERT and NET transporters. This action increases monoamine concentration in the synaptic space, thereby enhancing the activity of the descending pain inhibitory pathway. This complementary mechanism supports the physiological function of nociceptive signal blockade within the spinal cord.

The drug is a racemic mixture, and this combination of central signal processing modulation and spinal signal transmission blockade influences physiological signaling through complementary pathways.

How Contramal retard is Used: Official Administration Guidelines

Contramal retard is formulated as prolonged-release tablets containing Tramadol Hydrochloride and is intended strictly for oral administration. The usage principles focus on maintaining a consistent therapeutic level of the active substance through a precise schedule, as required by its sustained-release design.

---

Standard Dosing and Administration

The dosage is typically initiated with the lowest effective amount and is subsequently adjusted based on the patient's specific needs, adhering to regulatory limits. The medication is commonly prescribed for a twice-daily schedule, with doses generally separated by a minimum of 8 hours.

Usage Constraint	Official Principle
Dosing Range	Initial doses often range from 50 mg to 100 mg twice daily. The total daily dose should generally not exceed 400 mg.
Ingestion Method	Tablets must be swallowed whole with sufficient liquid. They must not be crushed, chewed, or divided to preserve the prolonged-release action and prevent rapid absorption.
Timing	May be taken with or without food.

---

Duration of Use and Special Populations

Official guidelines state that treatment duration must be limited to the period absolutely necessary for pain control. If long-term use is required, regular medical monitoring is mandatory to assess the continued requirement for therapy.

For older adults over 75 years of age, the dosing interval may require extension due to the natural slowing of drug elimination, though this adjustment is not typically needed for patients under 75 years without organ impairment.

️ Evidence for Use in Chronic Moderate-to-Severe Pain

The prolonged-release formulation of tramadol was studied for its use in the context of chronic pain conditions that may require continuous analgesic support. The research base primarily consists of short-term Randomized Controlled Trials (RCTs) and subsequent analyses that explore how symptoms change over time in adult patients. These studies explored populations diagnosed with conditions where symptoms may vary in intensity, such as Osteoarthritis and Chronic Low Back Pain. The results from the trials describe symptom patterns observed within these specific groups.

The studies monitored outcomes related to physical discomfort and how patients reported their experience over the study period. Synthesis of the available data may indicate a small magnitude of reported change in standardized pain scores. Trials documented patient-reported patterns related to functional status. Evidence overall was observed in some studies to have low certainty and noted heterogeneity (variability) across the data.

---

Study Focus: Outcomes and Measures

Research examined several axes of patient experience. The primary focus of the trials was on outcomes related to symptom intensity or variability, typically measured using standardized scales. Beyond the measurements of core discomfort, studies also monitored outcomes reflecting daily functioning or activity level and measured how patients reported their ability to perform routine tasks. Furthermore, the trials also examined patient-reported outcomes describing perceived discomfort related to sleep quality. These findings help contextualize how patients reported their experience while the study was observed in the trial settings.

---

Data on Long-Term Use and Durability

The existing clinical evidence primarily focuses on short follow-up durations. The prolonged-release formulation was studied for use in periods requiring continuous analgesic support. However, follow-up durations were limited in the core randomized trials, generally not exceeding 16 weeks. Because of this, there is limited information for long-term outcomes that address potential sustained effects on daily functioning or symptom patterns beyond this initial period. Research so far indicates that studies report how symptoms evolved only in the observed short-term populations, and long-term effects are not fully established by the available controlled evidence.

---

‍‍‍ Evidence in Specific Patient Populations

The main body of evidence was evaluated in general adult populations with chronic, non-malignant pain. Research describes patterns observed in these studied groups. However, data for certain groups remain insufficient. Specifically, subgroup findings are uncertain for specific populations, such as older adults, adolescents, or patients with multiple chronic comorbid conditions that may influence how outcomes are measured or reported. The existing research provides context but not individual predictions for these groups.

---

Evidence Gaps and Areas of Research Uncertainty

Several limitations highlight areas where more research is needed. As noted, follow-up durations were limited, meaning that understanding of sustained effects is incomplete. Additionally, evidence quality varies across studies, and some trials included in the systematic reviews were noted to have a potential risk of bias, which contributes to the overall low certainty of the findings. The results apply only to the populations studied under the specific conditions of the trials. Overall, the research highlights what is known — and what is still uncertain — about this formulation in the broader evidence landscape.

Key Studies & References

1. Public Assessment Report (PAR) for Tramadol HCL Retard 100/150/200 mg, modified-release tablets (CBG-MEB)
2. Tramadol for the Management of Pain in Adult Patients: A Review of Clinical Effectiveness

Common questions about Contramal retard (FAQ)

Q: Does Contramal retard interact with common over-the-counter pain relievers like ibuprofen?

Official drug safety documents primarily focus on major interactions involving central nervous system depressants, certain anti-depressants, and MAOIs. These regulatory sources do not typically list over-the-counter non-opioid pain relievers like ibuprofen. Authoritative health sources often describe non-opioid pain relievers as having a generally low reported risk of interaction.

Q: Is it true that this medicine can affect driving ability?

Yes, official product information includes specific warnings that this medicine may cause side effects such as drowsiness, dizziness, and blurred vision. These effects can impair reactions and the ability to drive or safely operate machinery. Therefore, official warnings suggest avoiding these activities until the effects of the medicine are understood.

Q: What happens if I miss a scheduled dose of Contramal retard?

Regulatory patient information often describes a process for missed doses, which typically involves taking the dose as soon as it is remembered, unless it is close to the time for the next scheduled dose. It is stated that a double dose should not be taken to compensate for a missed dose. Maintaining the prescribed time interval is emphasized.

Q: Does Contramal retard show up on standard drug tests?

Yes. Tramadol, the active ingredient in Contramal retard, along with its main active metabolite (O-desmethyltramadol), can be detected by specific urine drug screening and confirmation tests. The drug is commonly included in toxicology panels used for medical monitoring.

Q: How quickly should I expect to feel relief after taking Contramal retard?

Contramal retard is a prolonged-release formulation, meaning it is specifically designed to release the active ingredient slowly over time. This mechanism provides sustained pain relief rather than rapid onset. Because of this controlled release, the full analgesic effect is expected to take longer to build up than formulations designed for rapid absorption.

Q: Are there different strengths of Contramal retard available?

Yes, official regulatory documents confirm that prolonged-release formulations of the active ingredient, Tramadol Hydrochloride, are typically available in multiple tablet strengths. Common strengths described in the labeling include, but are not limited to, 100 mg, 200 mg, and 300 mg tablets.

Q: What are the signs of an allergic reaction to Contramal retard?

Official safety sections list signs of a serious allergic reaction (anaphylaxis), which may include symptoms like a rash, hives, or severe swelling of the face, throat, or tongue. Difficulty breathing or severe dizziness are also listed as serious signs. If any of these symptoms are observed, seeking immediate medical attention is the recommended course of action.

Q: Is it safe to take herbal supplements while on Contramal retard?

Regulatory documents list known interactions with prescription medicines that affect the central nervous system or certain metabolic enzymes. Official information on combining tramadol with herbal or complementary remedies is limited. To maintain safety, authoritative health sources suggest that such combinations be avoided unless discussed with a healthcare professional.

Q: Does Contramal retard interact with blood pressure medication?

Official labeling indicates that the medicine itself carries a risk of causing severe hypotension (low blood pressure), including dizziness when standing. Due to this inherent risk of affecting blood pressure, official labeling implies that consideration is necessary when the medicine is used alongside any other medications that also affect blood pressure.

Q: Why do some sources mention a risk of hypoglycemia (low blood sugar) with tramadol?

While low blood sugar (hypoglycemia) is not typically included as a common side effect in the main regulatory documents, it has been documented in post-marketing reports and medical literature. This risk is noted in reports and medical literature, with some focus on patient groups such as older adults.

Q: Is it possible to be allergic to the ingredients in Contramal retard?

Yes, official regulatory information states that the medicine is contraindicated (not intended for use) if a patient has a known hypersensitivity (allergic reaction) to tramadol, any other opioid substance, or any of the other non-active ingredients in the tablet.

Storage Conditions

Contramal retard prolonged-release tablets must be stored according to official regulatory requirements to ensure stability and safety. The medicine should be stored below 30°C and must be kept away from excessive heat, moisture, and freezing. The tablets should remain in their original container to maintain integrity and protection from the environment.

Child-Safety Storage

Due to the significant risk of fatal overdose, it is mandatory to keep this opioid medicine out of the sight and reach of children at all times. It must be stored in a secure location where others cannot access it.

Disposal Instructions

Unused or expired Contramal retard must not be disposed of in household waste or flushed down the toilet. Disposal must follow local regulations for pharmaceutical waste, often requiring the product to be returned to a pharmacy or collection point.